Lytix Biopharma AS

OL:LYTIX Norway Biotechnology

Market Cap

$72.89 Million

Nkr830.52 Million NOK

Market Cap Rank

#23184 Global

#117 in Norway

Share Price

Nkr10.80

Change (1 day)

+1.89%

52-Week Range

Nkr4.80 - Nkr11.50

All Time High

Nkr18.60

Lytix Biopharma AS - Asset Resilience Ratio

Latest as of December 2025: 88.76%

Lytix Biopharma AS (LYTIX) has an Asset Resilience Ratio of 88.76% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

Nkr72.36 Million

Cash + Short-term Investments

Total Assets

Nkr81.52 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Lytix Biopharma AS's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Lytix Biopharma AS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Nkr10.60 Million	13.0%
Short-term Investments	Nkr61.76 Million	75.75%
Total Liquid Assets	Nkr72.36 Million	88.76%

Asset Resilience Insights

Very High Liquidity: Lytix Biopharma AS maintains exceptional liquid asset reserves at 88.76% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.